Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive
    Colaneri, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
    21/21 inconclusive
      HNF Hospital Tocilizumab multidisciplinary team, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
      20/25 suggested
      • suggested 87 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
      Martinez-Sanz, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
      260/969 suggested
      • suggested 66 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
      Tsai, 2020 OBStocilizumab controlCOVID 19 hospitalizedserious
      66/66 inconclusive

        COVID 19 all comers meta-analysis

        sarilumab phase 2 high dose unpublished
         
        NCT04315298
        RCTsarilumab high dose (400mg)placeboCOVID 19 all comershigh
        145/77 suggested
        • suggested 61 % decrease in death or ventilation but with a low degree of certainty due to high risk of bias
        • suggested 73 % decrease in ventilation but with a low degree of certainty due to high risk of bias
        there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group
        sarimulab phase 2 low dose unpublished
         
        NCT04315298
        RCTsarilumab low dose (200mg)placeboCOVID 19 all comershigh
        136/77 suggested
        • suggested 72 % decrease in ventilation but with a low degree of certainty due to high risk of bias
        there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group

        COVID-19 mild to moderate meta-analysis

        CORIMUNO-19, 2020
         
        NCT04331808
        RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
        64/67 inconclusive
          EMPACTA, 2020
           
          NCT04372186
          RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
          259/129 conclusif
          • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
          Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
          62/23 suggested
          • suggested 96 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

          COVID-19 severe or critically meta-analysis

          REMAP-CAP sarilumab, 2021
           
          NCT02735707
          RCTsarilumabstandard of careCOVID-19 severe or criticallysome concern
          48/402 conclusif
          • demonstrated 76 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          REMAP-CAP tocilizumab, 2021
           
          NCT02735707
          RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
          353/402 conclusif
          • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
          • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          Veiga, 2021
           
          NCT04403685
          RCTtocilizumab controlCOVID-19 severe or criticallysome concern
          65/64 safety concern
          • safety concern with 1.7-fold increase in deaths (not statistically significant)
          BACC Bay Tocilizumab Trial, 2020
           
          NCT04356937
          RCTtocilizumab placeboCOVID-19 severe or criticallylow
          161/81 inconclusive
          • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
          COVACTA (Rosas), 2020
           
          NCT04320615
          RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
          294/144 inconclusive
            Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
            198/413 inconclusive
              ARI-RAF (Della-Torre), 2020 OBSsarilumabcontrolCOVID-19 severe or criticallyNA
              28/28 inconclusive
                Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
                210/420 suggested
                • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
                Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                30/29 suggested
                • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                96/97 inconclusive
                  Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                  78/76 safety concern
                  • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                  • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
                  TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
                  32/33 inconclusive

                    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).